FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2024455741> ?p ?o ?g. }

• W2024455741 endingPage "165" @default.
• W2024455741 startingPage "153" @default.
• W2024455741 abstract "International Journal of DermatologyVolume 23, Issue 3 p. 153-165 New Antibiotics New Hopes and New Problems Robert H. K. ENG M.D., Corresponding Author Robert H. K. ENG M.D. Infectious Disease Section, Veterans Administration Medical Center, East Orange, New Jersey and the Infectious Disease Division, Department of Medicine, University of Medicine and Dentistry of New Jersey, Newark, New JerseyAddress for reprints; Robert Eng, M.D., Medical Service (1 1 1), VA Medical Center, East Orange, NJ 07019.Search for more papers by this author Robert H. K. ENG M.D., Corresponding Author Robert H. K. ENG M.D. Infectious Disease Section, Veterans Administration Medical Center, East Orange, New Jersey and the Infectious Disease Division, Department of Medicine, University of Medicine and Dentistry of New Jersey, Newark, New JerseyAddress for reprints; Robert Eng, M.D., Medical Service (1 1 1), VA Medical Center, East Orange, NJ 07019.Search for more papers by this author First published: April 1984 https://doi.org/10.1111/j.1365-4362.1984.tb04505.xCitations: 3 Supported by the General Medical Research Fund of the East Orange Veterans Administration medical Center. AboutPDF ToolsRequest permissionExport citationAdd to favoritesTrack citation ShareShare Give accessShare full text accessShare full-text accessPlease review our Terms and Conditions of Use and check box below to share full-text version of article.I have read and accept the Wiley Online Library Terms and Conditions of UseShareable LinkUse the link below to share a full-text version of this article with your friends and colleagues. Learn more.Copy URL Share a linkShare onEmailFacebookTwitterLinkedInRedditWechat References 1 Rammelkamp CH. Moxon T: Resistance of Staphylococcus aureus to the activity of penicillin. Proc Soc Exp Biol Med 51: 386, 1942. 2 Findland M, Jones WF Jr, Barnes MW: Occurrence of serious infections since the introduction of antibiotic agents. JAMA 170: 2188, 1959. 3 Kreger BE, Craven DE, Carling PC et al: Gram-negative bacteremia. Am J Med 68: 332, 1980. 4 Curtis NAC: Penicillin-binding protein in theory and practice. J Antimicrob Chemother 8: 85, 1981. 5 Tomasz A: Susceptibility to B-lactam antibiotics: From inhibited target protein to inhibited target ceils In: Antibiotic in the Management of Infections. Edited by AGZ Beams, New York , Raven Press, 1982. 6 Richmond MH: Blactamase and gram-negative bacteria In: Cephalosporins: Dimensions and Future. Edited by B. Edselius Excerpta Medica. Amsterdam , 1974. 7 Nakae T, Nikaido H: The structural basis of outer membrane permeability in gram-negative bacteria. Nippon Saikingaku Zasshi 3: 715, 1978. 8 Mandell GL, Sande M: Antimicrobial agents: Penicillins and cephalosporins In: The Pharmacological Basis of Therapeutics. 6th ed. Edited by AC Gilman, LS Goodman. New York , MacMillan Publishing, 1980. 9 Izaki K, Matsuhashi M, Strominger JL: Glycopeptide transpetidase and D-alanine carboxypeptidase, penicillin-sensitive enzymatic reactions. Proc Natl Acad Sci USA 55: 656, 1966. 10 Neu HC: Antimicrobial activity and human pharmacology of amoxicillin. J Infect Dis 129 (suppl): S123, 1974. 11 Knudsen ET, Rolinson GN, Sutherland N: Carbenicillin: A new semisynthetic penicillin active against Pseudomonas pyogenes. Br Med J 3: 75, 1967. 12 Swenson RM, Lorber B: Clindamycin and carbenicillin in treatment of patients with intraabdominal and female genital tract infections. J Infect Dis 135 (suppl): S40, 1977. 13 Sanders CC: Mezlocillin: A broad-spectrum penicillin highly active against gram-positive organisms and Haemophilus fluenzae. J Antimicrob Chemother 9 (suppl A): 15, 1982. 14 Cole M, Reading C: Clavulanic acid: A beta-lactamase-inhibiting beta-lactam from Streptomyces clavuligerus. Antimicrob Agents Chemother 11: 852, 1977. 15 Neu HC, Fu KP: Clavulanic acid, a novel inhibitor of B-lactamases. Antimicrob Agents Chemother 14: 650, 1978. 16 Paisley JW, Washington JA II: Combined activity of clavulanic acid and ticarcillin against ticarcillin-resistant, gram-negative bacilli. Antimicrob Agents Chemother 14: 224, 1978. 17 Barber M, Waterworth PM: Penicillinase-resistant penicillins and cephalosporins. Br Med J 2: 344, 1964. 18 Kirby WM, Regamey C: Pharmacokinetics of cefazolin compared with four other cephalosporins. J Infect Dis 128 (suppl): S341, 1973. 19 Ernst EC, Berger S, Barza M, et al: Activity of cefamandole and either cephalosporins against aerobic and anaerobic bacteria. Antimicrob Agents Chemother 9: 852. 1976. 20 Moellering RC, Dray RM, Kunz LJ: Susceptibility of clinical isolates of bacteria to cefoxitin and cephalothin, Antimicrob Agents Chemother 6: 320, 1974. 21 Eng RHK, Smith SM, Cherubin C: Observations of inoculum effect in Pseudomonas aeruginosa with the new cell-wall antibiotics. (in press). 22 Farber B, Moellering RC: The third generation cephalosporins. Bull NY Ac ad Med 58: 696, 1982. 23 Yu V: Enterococcal superinfection and colonization after therapy with moxalactam, a new broadspectrum antibiotic, Ann Intern Med 44: 784, 1981. 24 Yoshida T: Structure function relationships of 1-oxycophems and moxalactam In: New Betalactam Antibiotics: A Review from Chemistry to Clinical Efficacy of the New Cephalosporins, Edited by HC Neu. Philadelphia . Francis Clark Institute, 1982. 25 Stoeckel K: Pharmacokinetics of Rocephin, a highly active new cephalosporin with an exceptionally long biological half-life, Chemotherapy 29 (suppl): 42, 1981. 26 Weitekamp MR, Aber RC: Prolonged bleeding times and bleeding diathesis associated with moxalactam administration, JAMA 249: 69, 1983. 27 Lipsky JJ: N-methyl-thio-tetrazole inhibition of the gamma carboxylation ot glulamic acid: Possible mechanism for antibiotic-associated hypoprothrombinemia. Lancet ii: 192, 1983. 28 Bang NU, Teasler SS, Meidenreich RO et al: Effects of moxalactam on blood coagulation and platelet function. Rev Infect Dis 4 (suppl): S546, 1982. 29 Brown CH III, Natelson EA, Bradshaw WM et al: The hemostatic defect produced by carbenicillin, N Engl J Med 291: 265, 1974. 30 Ferres H, Nunn B: Penicillin metabolites and platelet function. Lancet ii: 226, 1983. 31 Buening MK, Wold JS: Akohol-moxalactam interactions in vivo. Symposium on a new generation of beta-lactam antibiotics, London, 1981. 32 Corrado ML, Landesman SH. Cherubin CE: Influence of inoculum size on activity of cepholperozone, cephopaxine, moxalactam, piperacillin, and N-formimidoyl thienamycin (MK 0787) against Pseudomonas originosum. Antimicrob Agents Chemother 18: 893, 1980. 33 Wolfe JC, Johnson WD Jr: Penicillin-sensitive streptococcal endocarditis, Ann Intern Med 81: 178, 1974. 34 Center for Disease Control: Gonorrhea: Recommended treatment schedules, 1979, Ann Intern Med 90: 809, 1979. 35 Reynolds AV, Hamilton-Miller JMT, Brumfitt W: Newer aminoglycosides–amikacin and tobramycin: an in vitro comparison with knanamycin and gentamicin. Br Med J 3: 778, 1974. 36 Regamey C, Shaberg D, Kirby WM: Inhibitory effect of heparin on gentamicin concentrations in blood, Antimicrob Agents Chemother 1: 329, 1972. 37 Bryan LE, Koward SK, Van Den Elzen HM: Effect of membrane energy mutations and cations on streptomycin and gentamicin accumulation by bacteria: A model for entry of streptomycin and gentamicin accumulation by bacteria, Antimicrob Agents Chemother 12: 163, 1977. 38 Davis J, Courvalin P: Mechanism of resistance to amino glycosides. Am J Med 62: 868, 1977. 39 Finegold SM, Sutter VL: Susceptibility of gram-negative anaerobeic bacilli to gentamicin and other aminoglycosides, J Infect Dis I 24: S56, 1971. 40 Pestka S: Inhibitors of ribosome functions, Ann Rev Microbiol 125: 487, 1971. 41 Davis J: Bacterial resistance to aminoglycoside antibiotics. J Infect Dis 124 (suppl); S7, 1971. 42 Mitsuhashl S, Kawabe H: Aminoglycoside antibiotic resistance in bacteria In: The Aminoglycosides: Microbiology, Clinical Use and Toxicity, Edited by A Whelton, HC Neu, New York , Marcel Dekker, 1982. 43 Roberts NJ Jr, Douglas RG: Gentamicin use and Paeudomonas and Serratia resistance: Eftect of a surgical prophylaxis regimen, Antimicrob Agents Chemother 13: 214, 1978. 44 Briedis DJ. Robson HG: Comparative activity of netilmicin, gentamicin, amikacin, and tobramycin against Pscudomonas aeruginosa and Enterobacter. Antimicrob Agents Chemother 10: 592, 1976. 45 Houang ET, Greenwood D: Aminoglycoside cross-resistance patterns of gentamicin-resistant bacteria, J Clin Pathol 30: 738, 1977. 46 Sande M, Mandell GL: Antimicrobial agents: The aminoglycosides In: The Pharmacological Basis of Therapeutics. 6th ed. Edited by AG Gilman, LS Goodman, A Gilman, New York , MacMillan, 1980, pp 1162–1180. 47 Morin JP, Fillastre JP: Aminoglycoside induced lysosomal dysfunctions in kidney In: The Aminoglycosides: Microbiology, Clinical Use, and Toxicology. Kidney Disease, vol, 2. Edited by A Whelton, H. Neu New York . Marcel Dekker.1982, pp 303–324. 48 Whelton A: Renal transport and intrarenal aminoglycoside distribution In: The Aminoglycosides: Microbiology, Clinical Use, and Toxicology, Kidney Disease, vol. 2, Edited by A Whelton, H Neu, New York , Marcel Dekker, 1982, pp 191–222. 49 Silverblatt FJ, Autoradiographic studies of intracellular aminoglycoside disposition in the kidney. In:. Aminoglycosides: Microbiology, Clinical Use, and Toxicology, Kidney Disease, vol. 2. Edited by A. Whelton H Neu, New York , Marcel Dekker, 1982. pp 223–233. 50 Houghton DC, Campbell-Boswell MV, Bennett WM et al: Myeloid bodies in the renal tubules of humans: Relationship to gentamicin therapy, Clin Nephrol 10: 140, 1978. 51 Bendirdjian JP, Fillastre JP, Foucher B: Mitochondria modifications with the aminoglycosides In: The Aminoglycosides: Microbiology, Clinical Use, and Toxicology, Kidney Disease, vol, 2, Edited by A Whelton, H. Neu New York , Marcel Dekker, 1982, pp 325–354. 52 Wade JC, Smith CR, Petty BG et al: Cephalothin plus an aminoglycoside is more nephrotoxic than methicillin plus aminoglycoside. Lancet 3: 604, 1978. 53 Martin CM, Cuomo AJ, Geraghty MJ et al: Gram-negative rod bacteremia, J Infect Dis 119: 506, 1969. 54 Cox CE, Harris LH: Comparison of gentimicin and polymyxin B-kanamycin in the therapy of bacteremia due to gram-negative bacilli, J Infect Dis 124 (suppl): Sl56, 1971. 55 Smith CR, Baughman KL, Edwards CQ et al: Controlled comparison of amikacin and gentamicin, N Engl J Med 296: 349, 1977. 56 Lau WK, Young LS, Black RE et al: Comparative efficacy and toxicity of amikacin/carbenicillin versus gentamicin/carbenicillin in leukopenic patients. Am J Med 62: 959, 1977. 57 Gilbert DN. Eubanks N, Jackson J: Comparison of amikacin and gentamicin in the treatment of urinary tract infections. Am J Med 62: 924, 1977. 58 Lerner SA, Seligsohn R, Matz GJ: Comparative clinical studies of ototoxicity and nephrotoxicity of amikacin and gentamicin. Am J Med 62: 919, 1977. 59 Keathing MJ. Bodey GP, Valdivieso M et al: A randomized comparative trial of three aminoglycosides: Comparisons of continuous infusions of gentamicin, amikacin and sisomicin combined with carbenicillin in the treatment of infections in neutropenic patients with malignancies. Medicine 58: 159, 1979. 60 Love LJ, Schimpff SC, Hahn DM et al: Randomized trial of empiric antibiotic therapy with ticarcillin in combination with gentamicin, amikacin or netilmicin in febrile patients with granulocytopenia and cancer. Am J Med 66: 603, 1979. 61 Klastersky J, Hensgens C, Henri A et al: Comparative clinical study of tobramycin and gentamicin. Antimicrob Agents Chemother 5: 133, 1974. 62 Madsen PO, Kjaer TB, Mosegaard A: Comparison of tobramycin and gentamicin in the treatment of complicated urinary tract infections. J Infect Dis 134 (suppl): Sl50, 1976. 63 Walker BD, Gentry LO: A randomized, comparative study of tobramycin and gentamicin in treatment of acute urinary tract Infections. J Infect Dis 134 (suppl):S146, 1976. 64 Gentry LO: Efficacy and safety of cefamandole plus gentamicin or tobramycin in therapy of severe gram-negative bacterial infections. J Infect Dis 137 (suppl); S144, 1978. 65 Parry MF, Neu HC: A comparative study of ticarcillin plus tobramycin versus carbenicillin plus gentamicin for the treatment of serious infections due to gram-negative bacilli. Am J Med 64: 961, 1978. 66 Wade JC. Smith CR, Petty BG. et al: Cephalothin plus an aminoglycoside is more nephrotoxic than methicilln plus aminoglycoside. Lancet ii; 604, 1978. 67 Fee WE Jr, Vierra V, Lathrop GR; Clinical evaluation of aminoglycoside toxicity: Tobramycin versus gentamicin, a preliminary report. J Antimicrob Chemotber 4 (suppl): 31, 1978. 68 Kahlmeter G, Hallberg T, Kamme C: Gentamicin and tobramycin in patients with various infections: Concentrations in serum and urinary excretion. J Antimicrob Chemother 4 (suppl): 37, 1978. 69 Schentag JJ, Plaut ME, Cerra FB et al: Aminoglycoside nephfotoxicity in critically ill surgical patients. J Surg Res 26: 270, 1979. 70 Smith CR, Lipsky JJ, Laskin OL et al: Double-blind comparison of the nephrotoxicity and auditory toxicity of gentamicin and tobramycin. N Engl J Med 302: 1106, 1980. 71 Klastersky J, Hensgens C, Gerard M et al: Comparison of sisomicin and gentamicin in bacteriuric patients with underlying diseases of the urinary tract. Antimicrob Agents Chemother 7: 742, 1975. 72 Madson PO, Kjaer TB, Mosegaard A: Comparison of tobramycin and gentamicin in the treatment of complicated urinary tract infections: Comparative study of sisomicin and gentamicin. Urology 9: 635, 1977. 73 Feld R, Valdivieso M, Bodey GP et al: Comparison of amikacin and tobramycin in the treatment of infection in patients witb cancer. J Infect Dis 135: 61, 1977. 74 Maigaard S, Frimodt-Moller N, Madsen PO: Comparison of netilmicin and amikacin in treatment of complicated urinary tract infections. Antimicrob Agents Chemotber 14: 544, 1978. 75 Lerner AM, Reyes MD, Cone LA, et al: Randomized, controlled trial of the comparative efficacy, auditory toxicity, and nephrotoxicity of tobramycin and netilmicin. Lancet ii: 1123, 1983. 76 Iinuma T, Mizukosbi O, Daly JF: Possible effects of various ototoxic drugs upon the ATP-hydrolyzing system in the atria vascularis and spiral ligament of the guinea pig. Laryngoscope 77: 159, 1969. 77 Benitez JT, Scbuknecbt HF, Brandengurg JH: Pathologic changes in human ear after kanamycin. Arch Otolaryngol 75: 192, 1962. 78 Hawkins JE Jr.: Antibiotics and the inner ear. Trans Am Acad Opthalmol Otolaryngol 63: 206, 1959. 79 Luft FC: An overview of aminoglycoside toxicity In: Clinical Significance of Aminoglycoside Toxicity (Schering Corp.). Pro Clinica, New York , 1983, pp 2–9. 80 Dahlgren JH, Anderson ET, Hewitt WL: Gentamicin blood levels: A guide to nephrotoxicity. Antimicrob Agents Chemother 8: 58, 1975. 81 Schentag JJ, Jusko WJ, Vance JW et al: Gentamicin disposition and tissue accumulation on multiple dosing. J Pbarmacokinet Biopharm 5: 559, 1977. 82 Kahmeter G: Nephrotoxicity of gentamicin and tubramycin. Scand J Infect Dis 8 (suppl): S15, 1979. Citing Literature Volume23, Issue3April 1984Pages 153-165 ReferencesRelatedInformation" @default.
• W2024455741 created "2016-06-24" @default.
• W2024455741 creator A5030209337 @default.
• W2024455741 date "1984-04-01" @default.
• W2024455741 modified "2023-10-09" @default.
• W2024455741 title "New Antibiotics." @default.
• W2024455741 cites W1484914833 @default.
• W2024455741 cites W1509902852 @default.
• W2024455741 cites W1966845303 @default.
• W2024455741 cites W1967575564 @default.
• W2024455741 cites W1967781339 @default.
• W2024455741 cites W1970964036 @default.
• W2024455741 cites W1972863789 @default.
• W2024455741 cites W1975948989 @default.
• W2024455741 cites W1977311889 @default.
• W2024455741 cites W1979405456 @default.
• W2024455741 cites W1981716879 @default.
• W2024455741 cites W1985242603 @default.
• W2024455741 cites W1986195502 @default.
• W2024455741 cites W1986207892 @default.
• W2024455741 cites W1989653273 @default.
• W2024455741 cites W1990049225 @default.
• W2024455741 cites W1997107396 @default.
• W2024455741 cites W2005450426 @default.
• W2024455741 cites W2006473422 @default.
• W2024455741 cites W2009717401 @default.
• W2024455741 cites W2018345501 @default.
• W2024455741 cites W2020396335 @default.
• W2024455741 cites W2021103976 @default.
• W2024455741 cites W2029487461 @default.
• W2024455741 cites W2030318306 @default.
• W2024455741 cites W2031919408 @default.
• W2024455741 cites W2035064963 @default.
• W2024455741 cites W2040282320 @default.
• W2024455741 cites W2045585264 @default.
• W2024455741 cites W2049332147 @default.
• W2024455741 cites W2060688539 @default.
• W2024455741 cites W2063165676 @default.
• W2024455741 cites W2076167539 @default.
• W2024455741 cites W2077315209 @default.
• W2024455741 cites W2077663024 @default.
• W2024455741 cites W2081809949 @default.
• W2024455741 cites W2082504040 @default.
• W2024455741 cites W2082601827 @default.
• W2024455741 cites W2084655721 @default.
• W2024455741 cites W2084779863 @default.
• W2024455741 cites W2086492203 @default.
• W2024455741 cites W2087475183 @default.
• W2024455741 cites W2090750145 @default.
• W2024455741 cites W2090959569 @default.
• W2024455741 cites W2094366191 @default.
• W2024455741 cites W2100756858 @default.
• W2024455741 cites W2111526274 @default.
• W2024455741 cites W2112950834 @default.
• W2024455741 cites W2139078471 @default.
• W2024455741 cites W2145793684 @default.
• W2024455741 cites W2151476311 @default.
• W2024455741 cites W2155276234 @default.
• W2024455741 cites W2164578098 @default.
• W2024455741 cites W2317592083 @default.
• W2024455741 cites W2325023166 @default.
• W2024455741 cites W2326033082 @default.
• W2024455741 cites W2332740972 @default.
• W2024455741 cites W2334676005 @default.
• W2024455741 cites W2335061041 @default.
• W2024455741 cites W4235153989 @default.
• W2024455741 cites W4241307929 @default.
• W2024455741 cites W4248355435 @default.
• W2024455741 doi "https://doi.org/10.1111/j.1365-4362.1984.tb04505.x" @default.
• W2024455741 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/6373637" @default.
• W2024455741 hasPublicationYear "1984" @default.
• W2024455741 type Work @default.
• W2024455741 sameAs 2024455741 @default.
• W2024455741 citedByCount "3" @default.
• W2024455741 crossrefType "journal-article" @default.
• W2024455741 hasAuthorship W2024455741A5030209337 @default.
• W2024455741 hasConcept C16005928 @default.
• W2024455741 hasConcept C501593827 @default.
• W2024455741 hasConcept C71924100 @default.
• W2024455741 hasConcept C86803240 @default.
• W2024455741 hasConcept C89423630 @default.
• W2024455741 hasConceptScore W2024455741C16005928 @default.
• W2024455741 hasConceptScore W2024455741C501593827 @default.
• W2024455741 hasConceptScore W2024455741C71924100 @default.
• W2024455741 hasConceptScore W2024455741C86803240 @default.
• W2024455741 hasConceptScore W2024455741C89423630 @default.
• W2024455741 hasIssue "3" @default.
• W2024455741 hasLocation W20244557411 @default.
• W2024455741 hasLocation W20244557412 @default.
• W2024455741 hasOpenAccess W2024455741 @default.
• W2024455741 hasPrimaryLocation W20244557411 @default.
• W2024455741 hasRelatedWork W1506200166 @default.
• W2024455741 hasRelatedWork W1995515455 @default.
• W2024455741 hasRelatedWork W2048182022 @default.
• W2024455741 hasRelatedWork W2080531066 @default.
• W2024455741 hasRelatedWork W2604872355 @default.
• W2024455741 hasRelatedWork W2748952813 @default.
• W2024455741 hasRelatedWork W2899084033 @default.

• next